title: Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
abstract: OBJECTIVE
  The potential and limitations of the established cytotoxic chemotherapy for acute myeloid leukemia have been assessed by recent large-scale clinical trials. A further progress would require the contribution of alternative approaches.
  
  
  RESULTS
  Early results from more specific, less toxic, targeted agents are now available. Major options under investigation are demethylating drugs and inhibitors of tyrosine kinases, farnesylation and angiogenesis.
  
  
  CONCLUSIONS
  Some of the novel agents, such as demethylating drugs, appear predestined for prolonged maintenance treatment due to their delayed antileukemic mechanism.
authors.affiliation: Department of Medicine, Hematology/Oncology, University of Münster, Münster, Germany.
authors.forename: Utz
authors.initials: U
authors.lastname: Krug
authors.forename: Michael
authors.initials: M
authors.lastname: Lübbert
authors.forename: Thomas
authors.initials: T
authors.lastname: Büchner
mesh_terms: D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D054876:Prenylation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000627:therapeutic use; D000077157:Sorafenib; D019311:Staurosporine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D001557:Benzenesulfonates; D004791:Enzyme Inhibitors; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077209:Decitabine; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases; D019311:Staurosporine; C059539:midostaurin; D001374:Azacitidine